XML 45 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Goodwill and Other Intangibles (Tables)
 9 Months Ended
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
Changes in the carrying amount of our goodwill for the nine months ended September 30, 2020 were as follows (in thousands):
Branded PharmaceuticalsSterile InjectablesGeneric PharmaceuticalsInternational PharmaceuticalsTotal
Goodwill as of December 31, 2019$828,818 $2,731,193 $— $35,173 $3,595,184 
Effect of currency translation— — — (2,387)(2,387)
Goodwill impairment charges— — — (32,786)(32,786)
Goodwill as of September 30, 2020$828,818 $2,731,193 $— $— $3,560,011 
The carrying amounts of goodwill at September 30, 2020 and December 31, 2019 are net of the following accumulated impairments (in thousands):
Branded PharmaceuticalsSterile InjectablesGeneric PharmaceuticalsInternational PharmaceuticalsTotal
Accumulated impairment losses as of December 31, 2019$855,810 $— $3,142,657 $500,417 $4,498,884 
Accumulated impairment losses as of September 30, 2020$855,810 $— $3,142,657 $522,184 $4,520,651 
Schedule of other intangible assets
Changes in the amount of other intangible assets for the nine months ended September 30, 2020 were as follows (in thousands):
Cost basis:Balance as of December 31, 2019AcquisitionsImpairmentsOther (1)Effect of Currency TranslationBalance as of September 30, 2020
Indefinite-lived intangibles:
In-process research and development$93,900 $— $— $(90,900)$— $3,000 
Total indefinite-lived intangibles$93,900 $— $— $(90,900)$— $3,000 
Finite-lived intangibles:
Licenses (weighted average life of 14 years)
$457,402 $— $(8,700)$— $— $448,702 
Tradenames6,409 — — — — 6,409 
Developed technology (weighted average life of 11 years)
5,844,439 — (57,071)(15,428)(6,633)5,765,307 
Total finite-lived intangibles (weighted average life of 11 years)
$6,308,250 $— $(65,771)$(15,428)$(6,633)$6,220,418 
Total other intangibles$6,402,150 $— $(65,771)$(106,328)$(6,633)$6,223,418 
Accumulated amortization:Balance as of December 31, 2019AmortizationImpairmentsOther (1)Effect of Currency TranslationBalance as of September 30, 2020
Finite-lived intangibles:
Licenses$(410,336)$(6,162)$— $— $— $(416,498)
Tradenames(6,409)— — — — (6,409)
Developed technology(3,414,138)(319,639)— 108,328 3,800 (3,621,649)
Total other intangibles$(3,830,883)$(325,801)$— $108,328 $3,800 $(4,044,556)
Net other intangibles$2,571,267 $2,178,862 
__________
(1)Amounts include reclassification adjustments of $90.9 million from In-process research and development to Developed technology for certain assets that were placed in service during the nine months ended September 30, 2020. The remaining amounts primarily relate to the removal of certain fully amortized Developed technology intangible assets.
Schedule of future amortization expense For intangible assets subject to amortization, estimated amortization expense for the five fiscal years subsequent to December 31, 2019 is as follows (in thousands):
2020$428,828 
2021$394,331 
2022$379,640 
2023$336,465 
2024$298,198 
Schedule of intangible asset impairment charges including goodwill
During the three and nine months ended September 30, 2020 and 2019, the Company incurred the following goodwill and other intangible asset impairment charges (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Goodwill impairment charges$— $— $32,786 $151,108 
Other intangible asset impairment charges$2,020 $4,261 $65,771 $104,660